I was against those awards and voted against all BODs last time. All the current management should step up and buy shares. The odd man out should replaced. CytoDyn needs change on the BOD. Gradual change one or two per year not a complete coup with potential for a corporate raid. The best defense for the current regime is for Corp charter amendments to prevent the excesses of the past and to add one or two independent industry expert board members to the current board and culling out a member or two. These new directors should not be from the 13d group as they are likely beholden to outside interests. Bruce Patterson might be an exception I would consider. The best course of action would be to form a partnership with a larger Biopharma to pursue one or more of the indications with said company buying 10% stake at higher price with a member of the BOD a clinical trial expert from said partnering Company. Nader needs to gradually turn over control to more experienced management. At some point CytoDyn will need a political heavyweight in the CEO position due to the disruptive nature of Leronlimab. Such was the need of Gilead when they installed Donald Rumsfeld as the CEO many years ago. Such a time for CytoDyn is approaching.
News 
Market Data 
Discover 
